{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-002403","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.105705+00:00","generated_at":"2026-06-27T19:43:25.859603+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Regeneron reports preliminary FY2021 U.S. EYLEA sales of $5.79B, REGEN-COV sales of $5.82B","bullets":["EYLEA FY2021 U.S. net product sales ~$5.79B (+17% YoY); Q4 sales ~$1.54B (+15% YoY).","REGEN-COV FY2021 U.S. net product sales ~$5.82B; Q4 sales ~$2.29B.","Provided corporate update at J.P. Morgan conference; highlighted pipeline progress including Aflibercept 8mg Ph3 data expected 2H22.","Dupixent annualizing at ~$6.6B run rate; three potential new Ph3 indications in 2022 (CSU, PN, EoE).","Announced $3B share repurchase program in Nov 2021; over $7.5B repurchased since Nov 2019."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-002403","json":"https://secwatch.observer/filing/0001104659-22-002403.json","markdown":"https://secwatch.observer/filing/0001104659-22-002403.md","text":"https://secwatch.observer/filing/0001104659-22-002403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465922002403/0001104659-22-002403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465922002403/tm222431d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:43:25.859603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}